Glimepirida Viatris (Glimepiride)

Glimepirida Viatris is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan. It may be used alone or in combination with other antidiabetic agents.

• Improves glycemic control when diet and exercise alone are insufficient.
• Can be combined with metformin, DPP‑4 inhibitors, or SGLT2 inhibitors for enhanced effect.
• May be prescribed for patients who have not achieved target HbA1c with other oral agents.
• Used in adults when a sulfonylurea is appropriate based on clinical judgment.
• Supports long‑term management of hyperglycemia in type 2 diabetes.

Glimepirida Viatris may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require prompt medical attention.

Common

• Hypoglycemia (low blood sugar)
• Nausea or abdominal discomfort
• Headache
• Dizziness or light‑headedness
• Weight gain
• Skin rash or itching

Serious

• Severe hypoglycemia leading to loss of consciousness
• Allergic reactions such as angioedema or Stevens‑Johnson syndrome
• Hepatic dysfunction (elevated liver enzymes)
• Hematologic abnormalities (e.g., leukopenia, thrombocytopenia)

Before starting Glimepirida Viatris, certain precautions should be considered to ensure safe use.

• Assess renal and hepatic function; dose adjustments may be needed.
• Use caution in elderly patients who are more prone to hypoglycemia.
• Monitor blood glucose regularly, especially when initiating therapy or changing dose.
• Avoid use during pregnancy and lactation unless benefits outweigh risks.
• Discontinue if signs of severe hypoglycemia or allergic reaction occur.
• Inform healthcare providers of all concurrent medications and medical conditions.

Glimepirida Viatris can interact with several drug classes, affecting its efficacy or safety profile.

Avoid

• Other sulfonylureas or insulin, which can increase risk of severe hypoglycemia.
• Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise glimepiride levels.
• MAO‑B inhibitors, which may potentiate hypoglycemic effects.

Use with caution

• Beta‑blockers, which can mask hypoglycemia symptoms.
• Thiazide diuretics, which may raise blood glucose.
• Antifungal agents like itraconazole that moderately inhibit metabolism.
• NSAIDs, which can affect renal function and glucose control.